Angiotensin receptor blockers are an interesting new class of drug for lowering blood pressure, and Micardis is the fifth one to be introduced in the US market; the others are Cozaar (losartan), Diovan (valsartan), Avapro (irbesartan), and Atacand (irbesartan). These drugs work by blocking the effects of angiotensin, which constricts blood vessels and promotes the secretion of a salt-retaining hormone called aldosterone; both of these effects will tend to raise the blood pressure.
The end result is similar to the effects of angiotensin converting enzyme (ACE) inhibitors, but unlike ACE inhibitors, the angiotensin receptor blockers don't cause cough as a side effect.
Micardis can be given in once daily dosage, alone or in combination with other antihypertensive drugs. Like other members of its class, it is more effective when given in combination with a diuretic. The usual starting dose is 40 milligrams, and doses of up to 160 milligrams are recommended. Side effects are rare, and similar to those of a placebo.
Micardis is marketed by Boehringer Ingelheim.